Chinese researcher granted European Gene Patent

‘Encoding chicken type II collagen (CCOL2A1) full-length gene and its application” was recently granted the “European Gene Patent” by the European Patent Office. This gene patent was invented by Professor Xi Yongzhi from China’s 307 Military Hospital. It will be China’s first internationally recognized European gene patent with high potential in its application in gene drugs to treat rheumatoid arthritis.

Read more here (in Chinese)

Vice-minister Buijink visits Huawei in Shanghai

Today vice-minister Buijink visited Huawei in Shanghai. He had a meeting with mr. Zhang, Senior vice president of Huawei.

The topics that they spoke about were among others experiences from Huawei in the Netherlands, the Dutch High-Tech knowledge and the cooperation and possible expansion with ACE.
Huawei Technologies Co. Ltd. is a Chinese multinational networking and telecommunications equipment and services company headquartered in Shenzhen, (Guangdong province). It is the largest telecommunications equipment maker in the world, after having overtaken Ericsson.

Huawei has over 140,000 employees, around 46% of whom are engaged in research and development (R&D). It has 20 R&D institutes in countries including China, the United States, Germany, Sweden, India, Russia, and Turkey, and in 2011 invested 23,696,000,000 CNY (3,743,612,560 USD) in R&D.

Huawei also has an establishment in Amsterdam focused on logistics. The T-mobile 3g network in the Netherlands is provided by Huawei. This is the first high-tech achievement on such a big scale by a Chinese company in Europe. KPN and Vodafone are also using equipement provided by Huawei. KPN chose Huawei to be one of the important suppliers of their UMTS and DWDM fiberglass network.

Chinese aim to be world technological power by 2049

“China aims to become a world technological power by 2049 and strives to be a leading nation in innovation and scientific development”. This almost prophetic announcement was made in document released by the Central Committee and the State Council last Sunday, as reported by Global Times. 2049 marks the last year of the Chinese Academy of Sciences roadmap “Science & Technology in China: A Roadmap to 2050 – Strategic General Report of the Chinese Academy of Sciences”.

The newly released document also sets the goal for the country to be “in the ranks of innovative nations” by 2020. No specifics are mentioned in the news release. It does reiterate spending targets for R&D. Spending as a part of GDP should reach 2.2% in the 12th Five-Year Plan (2011-15) period, and more than 2.5 percent by 2020. R&D spending in 2011 totalled 1.83% of GDP, or 139,7 bln USD. At the same time, R&D input for large- and medium-size industrial enterprises should increase to 1.5 percent of revenue in the 12 FYP period, and for every 10,000 employees, there should be at least 43 R&D personnel each year, according to the document.

Sino-Dutch Chemistry & Materials Seminar

On monday 24th of September a seminar with the topic on “The role of chemistry for future, advanced materials science” has taken place in Shanghai. H.E. Mr. Chris Buijink, Vice Minister Economic affairs, Agriculture and Innovation (EL&I), officially opened the seminar.
Participation in the seminar came from representatives from government, chemistry & materials companies and research institutes. In total there were 75 participants.

Purpose of the seminar was to strengthen the Sino-Dutch R&D cooperation in the field of chemistry and materials.

Chemistry has always been an indispensable contributor to materials science. Materials are synthesized from chemical precursors and assembled using processes requiring chemical transformations. The Dutch Top Sector Chemistry, Dutch companies active in China and Sino-Dutch R&D projects cover the whole chain from fundamental, chemical research to advanced material application. The seminar was a platform where new policies, developments and innovations were shared and success stories of Sino-Dutch collaboration were shown. Also developments towards a bio-based economy and its influence on for the chemical & materials sector were discussed.

Leiden University Medical Center and Guangzhou Institute of Biomedicine and Health to start collaboration

The Leiden University Medical Center (LUMC) and the Guangzhou Institute of Biomedicine and Health (GIBH), an institute under the Chinese Academy of Sciences, have announced the start of a collaboration project. The two parties will investigate and identify possible lead compounds for treatment of pulmonary arterial hypertention and fibrodysplasia ossificans progressiva by using patient-derived pluripotent stem cells. Pulmonary arterial hypertention and fibrodysplasia ossificans progressiva are two diseases that have been linked to mutations in bone morphogenetic protein receptors and for which no cure is currently available.

This collaboration is funded by the China Exchange Program, a funding program for individual visits or joint research programs aimed at fostering long-term research cooperation between the Netherlands and China. In the Netherlands the Royal Netherlands Academy of Arts and Sciences (KNAW) is responsible for administering the program. More information on the program can be found here.